Investors tend to be attracted to stocks that trade at a cheap price due to the fact that they offer the possibility of great returns for not a large amount of capital invested. Small-cap companies typically trade at a lower price compared to larger companies. Investors should be aware that stocks that trade at a cheap rate, such as below $10 per share, are inherently riskier than stocks with a strong financial position and great reputation. Cheap companies have a much higher chance of wild swings in their ...

Company achieved significant commercial progress in 2023 IBSRELA® now expected to generate greater than $1.0 billion in annual U.S. net product sales revenue at peak Webcast scheduled for 7:00 PM ET / 4:00 PM PT to discuss IBS-C Market WALTHAM, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today provided an update o ...

Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Conference Call October 31, 2023 8:00 AM ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Mike Raab - President & Chief Executive Officer Susan Rodriguez - Chief Commercial Officer Justin Renz - Chief Financial Officer & Chief Operations Officer Conference Call Participants Louise Chen - Cantor Yigal Nochomovitz - Citi Research Joseph Thome - TD Cowen Matt Kaplan - Ladenburg Thalmann Operator Good day and wel ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36485 ARDELYX, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-1303944 (State or Ot ...

Corporate Presentation Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Ardelyx, they are forward- looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including Ardelyx’s expectations regarding full year 2023 IBSRELA net sales revenue, potential commercial opportunities and other opportunities for the company, Ar ...

Ardelyx, Inc. (NASDAQ:ARDX) Q2 2023 Earnings Conference Call August 2, 2023 8:00 AM ET Company Participants Caitlin Lowie - Vice President, Corporate Communications and Investor Relations Mike Raab - President and Chief Executive Officer Susan Rodriguez - Chief Commercial Officer Justin Renz - Chief Financial and Operations Officer Conference Call Participants Yigal Nochomovitz - Citi Research Laura Chico - Wedbush Securities Peyton Bohnsack - TD Cowen Dennis Ding - Jeffries Matthew Kaplan - Ladenburg Thalm ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36485 ARDELYX, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-1303944 (State or Other J ...

Ardelyx, Inc. (NASDAQ:ARDX) Q1 2023 Results Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Caitlin Lowie - Vice President, Corporate Communications and Investor Relations Mike Raab - President and Chief Executive Officer Susan Rodriguez - Chief Commercial Officer Justin Renz - Chief Financial and Operations Officer Conference Call Participants Yigal Nochomovitz - Citi Research Laura Chico - Wedbush Securities Joseph Thome - TD Cowen Christopher Raymond - Piper Sandler & Co. Matthew Kap ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36485 ARDELYX, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-1303944 (State or Other ...

Financial Data and Key Metrics Changes - Net product sales for IBSRELA in Q4 2022 were $8.7 million, a 78% increase from Q3 2022 sales of $4.9 million [13][23] - Total revenue for IBSRELA for 2022 was $15.6 million, reflecting strong growth momentum [13][23] - Collaboration revenue for the full year 2022 was $36.6 million, compared to $10.1 million in 2021, with a significant portion from milestone payments [23] - Net income for Q4 2022 was approximately $11 million, or $0.06 per fully diluted share, while the net loss for the year was $67.2 million, a reduction from a net loss of $158.2 million in 2021 [25] Business Line Data and Key Metrics Changes - IBSRELA demonstrated significant quarter-over-quarter prescription growth, with over two-thirds of surveyed GIs reporting its unique mechanism of action [8][14] - The company expects to capture a mid to high single-digit share of the 5 million prescription IBS-C market, potentially yielding peak revenue of at least $500 million [10][12] Market Data and Key Metrics Changes - The market for hyperphosphatemia treatment is in need of new alternatives, with 77% of patients unable to maintain target levels despite existing treatments [16] - XPHOZAH is positioned as a first-in-class phosphate absorption inhibitor, addressing a significant unmet need in the market [17] Company Strategy and Development Direction - The company aims to develop innovative first-in-class medicines that meet significant unmet medical needs, with a focus on IBSRELA and XPHOZAH [7][12] - Ardelyx is preparing for the potential launch of XPHOZAH in the second half of 2023, leveraging its established commercial capabilities [18][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future potential of Ardelyx, highlighting the successful commercialization of IBSRELA and the path forward for XPHOZAH [28][62] - The company is focused on maximizing shareholder value while pursuing non-equity solutions for funding [26] Other Important Information - The company has a strong balance sheet with total cash and short-term investments of $123.9 million as of December 31, 2022 [25] - Ardelyx issued its first-ever ESG report, demonstrating its commitment to stakeholder issues [28] Q&A Session Summary Question: What is the latest expectation for cash runway? - Management indicated confidence in funding operations with approximately $121 million in cash as of February 28, 2023, and a cautious approach to spending [30][32] Question: Did anything happen in the Type A meeting that affected the review timeline? - Management maintained a base case expectation of a six-month review for the NDA resubmission, with no new insights suggesting a shorter timeline [33][34] Question: What is the gross to net ratio for IBSRELA? - The gross to net ratio for 2022 was approximately 28%, indicating a stable reduction [39][40] Question: Are there any risks of delays in the review process? - Management expressed confidence in the approval path for XPHOZAH, indicating that the appeal granted suggests a solid path to launch [41][42] Question: What are the preparations for the launch of XPHOZAH? - Preparations are well underway, with established commercial infrastructure and a dedicated nephrology salesforce ready to mobilize [52]